Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
A rare whale is having an encouraging season for births. Scientists warn it might still go extinct - 2Opening Potential: Self-awareness and Long lasting Learning
- 3JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis
- 4German men need approval for stays abroad under military service law
- 5the 6 Shrewd Beds for seniors: A Complete Survey
- Astronomers discover never-before-seen celestial object: "Cloud 9"
- Very good quality Greens All over The Planet
- Key Little Things That Advantage Old People
- Mobility exercises are an important part of fitness as we age. Here are some tips
- The Reduced Portage Horse: An Inheritance Reconsidered for Present day Experience
- Most loved Web-based feature: Which Stage Do You Like
- Americans generally like wolves − except when we’re reminded of our politics
- Best Pizza Beating: What's Your #1?
- From Dread to Certainty: Individual Accounts of Strengthening
